Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GPR84 | Q9NQS5 | 1/20 | 0.34 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.33 |
| ▸ | CYP2A6 | P11509 | 3/20 | 0.33 |
| ▸ | ALOX12 | P18054 | 1/20 | 0.33 |
| ▸ | TSHR | P16473 | 1/20 | 0.33 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.33 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.33 |
| ▸ | GPR3 | P46089 | 1/20 | 0.33 |
| ▸ | IDO1 | P14902 | 1/20 | 0.33 |
| ▸ | IMPDH2 | P12268 | 2/20 | 0.32 |
| ▸ | BRD4 | O60885 | 1/20 | 0.32 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.32 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19590889 | 0.78 | HTR2A (0.33) | ALDH1A1CYP2A6ALOX12TSHRHSD17B10 | |
| SCHEMBL20033962 | 0.75 | KDM4E (0.34) | ALDH1A1HSD17B10SMN1; SMN2KDM4E | |
| SCHEMBL22623683 | 0.73 | BRD4 (0.43) | ALDH1A1TSHRHSD17B10TDP1BRD4 | |
| SCHEMBL8149494 | 0.71 | CYP2A6 (0.41) | GPR84ALDH1A1CYP2A6TSHRHSD17B10 | |
| SCHEMBL19608698 | 0.70 | ALDH1A1 (0.39) | GPR84ALDH1A1CYP2A6TSHRHSD17B10 | |
| SCHEMBL19454794 | 0.70 | CYP2A6 (0.39) | GPR84ALDH1A1CYP2A6TSHRHSD17B10 | |
| SCHEMBL13657554 | 0.67 | GPR84 (0.34) | GPR84ALDH1A1CYP2A6TSHRHSD17B10 | |
| SCHEMBL22536926 | 0.67 | BRD4 (0.44) | ALDH1A1HSD17B10BRD4SMN1; SMN2KDM4E | |
| SCHEMBL11716121 | 0.67 | GPR84 (0.38) | GPR84ALDH1A1CYP2A6TSHRHSD17B10 | |
| SCHEMBL18233737 | 0.67 | GPR84 (0.34) | GPR84ALDH1A1CYP2A6TSHRHSD17B10 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 21 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20170066792-A1 | TETRADENTATE AND OCTAHEDRAL METAL COMPLEXES CONTAINING NAPHTHYRIDINOCARBAZOLE AND ITS ANALOGUES | ARIZONA BOARD OF REGENTS ON BEHALF OF ARIZONA STATE UNIVERSITY | 2017-03-09 | — | — | US | disclosed |
| US-20160074381-A1 | MODULATORS OF CELLULAR ADHESION | SARCODE BIOSCIENCE INC. (US) | 2016-03-17 | — | — | US | disclosed |
| US-9248126-B2 | Modulators of cellular adhesion | SARCODE BIOSCIENCE INC. (US) | 2016-02-02 | — | — | US | disclosed |
| US-9216174-B2 | Modulators of cellular adhesion | SARCODE BIOSCIENCE INC. (US) | 2015-12-22 | — | — | US | disclosed |
| US-20140066476-A1 | MODULATORS OF CELLULAR ADHESION | SARCODE BIOSCIENCE INC. (US) | 2014-03-06 | — | — | US | disclosed |
| US-20140051675-A1 | MODULATORS OF CELLULAR ADHESION | SARCODE BIOSCIENCE INC. (US) | 2014-02-20 | — | — | US | disclosed |
| US-20120035154-A1 | Modulators of Cellular Adhesion | SARcode Bioscience, Inc. (US) | 2012-02-09 | — | — | US | disclosed |
| US-8071617-B2 | Modulators of cellular adhesion | SARCODE BIOSCIENCE INC. (US) | 2011-12-06 | — | — | US | disclosed |
| US-7989626-B2 | Modulators of cellular adhesion | SAR code Corporation (US) | 2011-08-02 | — | — | US | disclosed |
| US-20110124625-A1 | Modulators of Cellular Adhesion | SARCODE CORPORATION (US) | 2011-05-26 | — | — | US | disclosed |
| US-7928122-B2 | Modulators of cellular adhesion | SARCODE CORPORATION (US) | 2011-04-19 | — | — | US | disclosed |
| US-7790743-B2 | Modulators of cellular adhesion | SARCODE CORPORATION (US) | 2010-09-07 | — | — | US | disclosed |
| US-7745460-B2 | Modulators of cellular adhesion | SARCODE CORPORATION (US) | 2010-06-29 | — | — | US | disclosed |
| US-20100093693-A1 | MODULATORS OF CELLULAR ADHESION | BAUSCH + LOMB IRELAND LIMITED (IE) | 2010-04-15 | — | — | US | disclosed |
| US-20080182839-A1 | MODULATORS OF CELLULAR ADHESION | SUNESIS PHARMACEUTICALS, INC. (US) | 2008-07-31 | — | — | US | disclosed |
| US-20080182839-A1 | MODULATORS OF CELLULAR ADHESION | SUNESIS PHARMACEUTICALS, INC. (US) | 2008-07-31 | — | — | US | disclosed |
| US-20080176896-A1 | Modulators of cellular adhesion | BAUSCH + LOMB IRELAND LIMITED (IE) | 2008-07-24 | — | — | US | disclosed |
| US-20080176896-A1 | Modulators of cellular adhesion | BAUSCH + LOMB IRELAND LIMITED (IE) | 2008-07-24 | — | — | US | disclosed |
| US-7314938-B2 | Immune and/or inflammatory disorders; autoimmune disorders; disorders mediated by the CD11/CD18 family of cellular adhesion molecules (e.g., LFA-1); antagonize CD11/CD18 receptors associated with leukocytes. | SUNESIS PHARMACEUTICALS, INC. (US) | 2008-01-01 | — | — | US | disclosed |
| US-7314938-B2 | Immune and/or inflammatory disorders; autoimmune disorders; disorders mediated by the CD11/CD18 family of cellular adhesion molecules (e.g., LFA-1); antagonize CD11/CD18 receptors associated with leukocytes. | SUNESIS PHARMACEUTICALS, INC. (US) | 2008-01-01 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140066476-A1 | MODULATORS OF CELLULAR ADHESION | ITGB1, VCAM1, ITGB8 | GPR84 246/4885ALDH1A1 112/4885CYP2A6 3358/4885 |
| US-20080176896-A1 | Modulators of cellular adhesion | ITGB1, VCAM1, ITGB8 | GPR84 246/4885ALDH1A1 112/4885CYP2A6 3358/4885 |
| US-20140051675-A1 | MODULATORS OF CELLULAR ADHESION | ITGB1, VCAM1, ITGB8 | GPR84 246/4885ALDH1A1 112/4885CYP2A6 3358/4885 |
| US-20100093693-A1 | MODULATORS OF CELLULAR ADHESION | ITGB1, VCAM1, ITGB8 | GPR84 250/4885ALDH1A1 119/4885CYP2A6 3408/4885 |
| US-20110124625-A1 | Modulators of Cellular Adhesion | ITGB1, VCAM1, ITGB8 | GPR84 246/4885ALDH1A1 112/4885CYP2A6 3358/4885 |
| US-20160074381-A1 | MODULATORS OF CELLULAR ADHESION | ITGB1, VCAM1, ITGB8 | GPR84 246/4885ALDH1A1 112/4885CYP2A6 3358/4885 |
| US-20170066792-A1 | TETRADENTATE AND OCTAHEDRAL METAL COMPLEXES CONTAINING NAPHTHYRIDINOCARBAZOLE AND ITS ANALOGUES | PAICS, DNTT, PNPO | GPR84 1087/4885ALDH1A1 4508/4885CYP2A6 3346/4885 |
| US-20120035154-A1 | Modulators of Cellular Adhesion | ITGB1, VCAM1, ITGB8 | GPR84 246/4885ALDH1A1 112/4885CYP2A6 3358/4885 |
| US-20080182839-A1 | MODULATORS OF CELLULAR ADHESION | ITGB1, VCAM1, ITGB8 | GPR84 249/4885ALDH1A1 111/4885CYP2A6 3376/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.